Therefore, it has been concluded that BDNF delivery should be localized [5] and targeted in specific brain regions, which are essential for the treatment of particular neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, multiple sclerosis, stroke, Rett syndrome, etc.). This evidence concerns the gene BDNF and early-onset autosomal dominant Alzheimer disease.